Energy coach tool – managing cancer related fatigue
Register and join the Leukaemia Foundation’s blood cancer online support service for free to access the energy coach to help manage cancer related fatigue.
Why access the digital energy coach?
- At least 6 in 10 people diagnosed with cancer report suffering from cancer related fatigue (CRF)
- CRF is a side-effect that has an enormous impact on quality of life
- managing CRF effectively can be life changing
What is a digital energy coach?
The energy coach enables members
- to record their daily energy levels each day over a week
- to recognise what affects their energy levels over seven days
- to see patterns, trends, and recommendations via evidence-based strategies
The Energy Coach is used to
- identify energy levels
- discover ways of managing fatigue
- provide tailored strategies to help with fatigue
Patient tip:
“I also love that the 3 selected tips/strategies are integrated back into the ‘My Dashboard’ section“
You will rate your:
- sleep
- diet
- exercise
- energy levels
and see how they all connect to your fatigue levels. We want to help you get back to doing the things you love.
Patient quote after using the energy coach:
“Love the energy coach! As promised, I completed the 7-day review and I think it’s a fantastic resource, with useful insights and fatigue management tips“
The energy coach is a 7 day program to help you understand and manage your cancer related fatigue.
Learn more
Need help?
Blood Cancers A-Z
A
AA secondary amyloidosis
Acute lymphoblastic leukaemia ALL
Acute myeloid leukaemia AML
Acute myelomonocytic leukaemia AMML
Acute promyelocytic leukaemia APML
Afib mutated fibrinogen alpha chain amyloidosis
AL systemic amyloidosis
Amyloidosis
Aplastic anaemia AA
ATTR familial amyloidotic polyneuropathy
ATTR wild type senile amyloidosis
B
Biphenotypic leukaemia
Bisphosphonates myeloma
C
Chronic lymphocytic leukaemia CLL
Chronic myeloid leukaemia CML
H
Hairy cell leukaemia
Hodgkin lymphoma
I
IgA myeloma
IgG myeloma
J
Juvenile myelomonocytic leukaemia JMML
L
Langerhans Cell Histiocytosis LCH
Leukaemia
Light chain myeloma
Lymphocyte depleted HL
Lymphocyte rich HL
Lymphoma
M
MDS with biallelic TP53 inactivation MDS-biTP53
MDS with fibrosis
MDS with hypoplastic MDS-h
MDS with increased blasts MDS-IB1
MDS with increased blasts MDS-IB2
MDS with low blasts MDS-LB
MDS with low blasts and isolated 5q deletion MDS-5q
MDS with low blasts and SF3B1 mutation MDS-SF3B1
Mixed cellularity HL
Monoclonal gammopathy of unknown significance MGUS
MPN Chronic eosinophilic leukaemia CEL
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic neutrophilic leukaemia CNL
MPN Essential thrombocythaemia ET
MPN Polycythaemia Rubra vera PV
MPN Primary myelofibrosis MF
MPN Systemic mastocytosis SM
Multiple myeloma
Myelodysplasia Myelodysplastic neoplasms MDS
Myeloma
Myeloid sarcoma localised leukaemia
Myeloproliferative neoplasms MPN
N
NHL Adult T-Cell leukaemic ATLL
NHL Anaplastic large cell ALCL
NHL Burkitt’s
NHL Cutaneous T-Cell
NHL Diffuse large B-cell DLBCL
NHL Double hit DHL
NHL Follicular
NHL Lymphoplasmacytic Waldenstrom’s macroglobulinaemia WM
NHL MALT
NHL Mantle cell
NHL Marginal zone
NHL Peripheral T-Cell
NHL Primary cutaneous B-cell
NHL Primary mediastinal B-cell PMBCL
NHL Small lymphocytic SLL
NHL Subcutaneous panniculitis-like T-Cell
NHL T-Lymphoblastic
NHL Waldenstroms macroglobulinaemia
Non-Hodgkin lymphoma
Nodular lymphocyte predominant HL
Nodular sclerosing HL
O
Osteosclerotic myeloma
P
Paroxysmal nocturnal haemoglobinuria
Plasmacytoma localised myeloma
POEMS syndrome
R
Richter’s syndrome leukaemia
S
Smouldering indolent myeloma
Solitary plasmacytoma myeloma
Systemic mastocytosis